Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

Background: As in other solid tumors, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis than patients with extensive metastatic disease. Stereotactic body radiotherapy (SBRT) is now considered...

Full description

Bibliographic Details
Main Authors: Maximilien Rogé, Yoann Pointreau, Paul Sargos, Emmanuel Meyer, Ulrike Schick, Ali Hasbini, Emmanuel Rio, Guillaume Bera, Amandine Ruffier, Magali Quivrin, Mathieu Chasseray, Igor Latorzeff, Etienne Martin, Valentine Guimas, Pascal Pommier, Thomas Leroy, Philippe Ronchin, Alexis Lepinoy, Audrey Grand, Lysian Cartier, Ossama Didas, Fabrice Denis, Vincent Libois, Audrey Blanc-Lapierre, Stéphane Supiot
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Prostate cancer
Oligorecurrent
Oligometastases
Stereotactic body radiotherapy
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630823000381

Internet

http://www.sciencedirect.com/science/article/pii/S2405630823000381

Similar Items